Actively Recruiting
Study Evaluating Alpelisib for Children and Adults with PIK3CA-related Overgrowth Spectrum PROS to Assess Effectiveness, Safety, and Drug Processing
Led by Novartis Pharmaceuticals · Updated on 2026-11-03
140
Participants Needed
40
Research Sites
124 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the daily oral medication alpelisib in children and adults with PIK3CA-related overgrowth spectrum PROS, a condition characterized by abnormal tissue growth. This Phase II study aims to demonstrate how well alpelisib works and to assess its safety and tolerability for people affected by PROS. The study includes a 48-week core treatment period followed by up to 2 years of extension periods to continue monitoring efficacy, safety, and how the body processes the drug. Adults start with 250 mg once daily, while children aged 6 to under 18 years start with 125 mg once daily, and children aged 2 to under 6 years start with 50 mg once daily. Participants receive alpelisib openly, without a placebo, and those benefiting from treatment may continue receiving alpelisib after the study ends. Participants undergo screening including whole body MRI to confirm eligibility and evaluate PROS lesions. During the study, researchers assess lesion volume changes through MRI, pain levels, symptom severity, and clinical responses at multiple timepoints up to 3 years. Safety is monitored by tracking adverse events, surgeries, hospital visits, and laboratory tests. The total study duration can extend over several years, ensuring thorough follow-up and monitoring.
CONDITIONS
Brief Title
EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)
Research Team
N
Novartis Pharmaceuticals
N
Novartis Pharmaceuticals
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here